deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT03388346

68Ga PSMA in Preprostatectomy Patients

68Ga PSMA-HBED-CC in Intermediate to High-Risk Preprostatectomy Patients

Sponsor: Holden Comprehensive Cancer Center

Conditions Prostate Cancer Prostatic Neoplasm Prostatic Neoplasm of Uncertain Behavior Prostatic Neoplasms, Castration-Resistant
Interventions Ga-68 PSMA-HBED-CC PET
Updated 12 times since 2018 Last updated: Jan 22, 2024 Started: Feb 16, 2018 Primary completion: Jul 22, 2021 Completion: Jul 22, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03388346, this PHASE2/PHASE3 trial focuses on Prostate Cancer and Prostatic Neoplasm and remains completed. Sponsored by Holden Comprehensive Cancer Center, it has been updated 12 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshotNot Yet Recruiting~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshotEnrolling By Invitation~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshotEnrolling By Invitation~Jan 2019 – ~Jun 2020 · 17 months · monthly snapshotEnrolling By Invitation~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshotEnrolling By Invitation~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshotEnrolling By Invitation~Feb 2021 – ~Feb 2023 · 24 months · monthly snapshotActive Not Recruiting~Feb 2023 – ~Jan 2024 · 11 months · monthly snapshotUnknown Status~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshotActive Not Recruiting~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

    Status: Active Not Recruiting → Completed

  4. Jan 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Unknown Status → Active Not Recruiting

  5. Feb 2023 — Jan 2024 [monthly]

    Unknown Status PHASE2_PHASE3

    Status: Active Not Recruiting → Unknown Status

▶ Show 7 earlier versions

  1. Feb 2021 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Enrolling By Invitation → Active Not Recruiting

  2. Jan 2021 — Feb 2021 [monthly]

    Enrolling By Invitation PHASE2_PHASE3

  3. Jun 2020 — Jan 2021 [monthly]

    Enrolling By Invitation PHASE2_PHASE3

  4. Jan 2019 — Jun 2020 [monthly]

    Enrolling By Invitation PHASE2_PHASE3

  5. Jun 2018 — Jan 2019 [monthly]

    Enrolling By Invitation PHASE2_PHASE3

  6. Mar 2018 — Jun 2018 [monthly]

    Enrolling By Invitation PHASE2_PHASE3

    Status: Not Yet Recruiting → Enrolling By Invitation · Phase: PHASE2 → PHASE2_PHASE3

  7. Jan 2018 — Mar 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Holden Comprehensive Cancer Center
  • Michael Graham PhD, MD
  • University of Iowa
Data source: University of Iowa

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations